PPAR-alpha L162V polymorphism in human hepatocellular carcinoma

Area of Science:

• Genetics
• Hepatology
• Oncology

Background:

• Peroxisome proliferator-activated receptor alpha (PPARα) is implicated in hepatocarcinogenesis.
• The L162V polymorphism in the PPARα gene increases its transactivation activity.
• Understanding PPARα L162V frequency in viral hepatitis-induced hepatocellular carcinoma (HCC) is crucial.

Purpose of the Study:

• To determine the frequency of the PPARα L162V polymorphism in patients with HCC.
• To investigate the clinical correlations of this polymorphism in HCC.
• To compare the prevalence of PPARα L162V polymorphism between hepatitis B virus (HBV) and hepatitis C virus (HCV) etiologies.

Main Methods:

• A case-control study involving 90 HCC patients and 80 healthy controls.
• PPARα L162V polymorphism was analyzed using Polymerase Chain Reaction-Restriction Fragment Length Polymorphism (PCR-RFLP).
• Patient data included HCC etiology, cirrhosis status, and tumor stage.

Main Results:

• The PPARα L162V polymorphism was found in 7.2% of HCC patients and 2.5% of controls (p=0.162).
• A higher prevalence was observed in HBV-infected patients (9.7%) compared to controls (2.5%) (p=0.071).
• The polymorphism was absent in HCV-related HCC and frequently associated with advanced disease (5/6 patients).

Conclusions:

• The PPARα L162V polymorphism shows a tendency towards occurrence in HBV-induced HCC, contrasting with HCV-related HCC.
• Different carcinogenesis mechanisms may exist between HBV and HCV-induced HCC.
• The association with advanced disease suggests a role for PPARα L162V polymorphism in HCC tumor progression.